Parnax Lab Peer Comparison

BSE: 506128

₹128.40

₹4.99 (4.04%)

As on 28-Aug-2026IST

Market cap

₹154 Cr

Revenue (TTM)

₹252 Cr

P/E Ratio

17.2

P/B Ratio

1.6

Div. Yield

0 %

Edit

	Parnax Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	154	21,501	19,125	18,253	17,766
Revenue (₹ Cr)	252	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	8.95	735.15	678.07	666.92	169.62
Net Margin (%)	3.50	26.88	28.10	20.60	6.90
RoE (%)	10.86	19.16	19.73	18.75	20.76
Price to Earnings	17.23	29.25	28.74	28.35	104.74
Price-To-Book	1.61	4.88	5.08	4.51	19.65

Income Statement (₹ Cr)

	Parnax Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	251.97	2,569.77	2,287.33	3,229.67	2,432.06
Total Income	255.72	2,735.39	2,413.29	3,237.12	2,458.54
Total Expenditure	227.85	1,628.14	1,490.75	2,090.06	2,202.20
EBITDA	24.12	941.63	796.58	1,139.61	229.86
Depreciation	8.33	57.58	78.10	281.06	17.24
EBIT	15.79	884.05	718.48	858.55	212.62
Interest	6.13	7.69	0.88	190.64	5.72
Other Income	3.75	165.62	125.96	7.45	26.48
Exceptional Items	-1.37	-49.16	0.00	-17.24	-5.13
Profit before Tax	12.05	992.82	843.56	658.12	228.25
Provision for Tax	3.10	257.67	165.49	-8.80	58.63
Profit after Tax	8.95	735.15	678.07	666.92	169.62

	Parnax Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	95.14	4,202.90	3,586.42	3,902.67	872.79
Minority Interest	-0.01	0.00	-12.71	-21.81	0.00
Non-Current Liabilities	36.48	91.50	28.74	1,392.75	134.50
Current Liabilities	95.85	627.48	385.94	2,077.10	981.81
Total Liabilities	189.82	4,911.11	3,207.85	6,862.28	1,879.19

	Parnax Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	118.89	770.28	1,291.22	5,617.77	42.47
Current Assets	93.04	3,803.22	2,585.66	1,539.85	1,739.93
Total Assets	189.82	4,911.11	3,207.85	6,862.28	1,879.19
Total Debt*	60.64	2.50	0.55	2,421.66	0.00
Net Current Assets	-2.81	3,175.74	2,199.72	-537.25	758.12
Contingent Liabilities	1.46	363.79	0.64	64.29	98.41

	Parnax Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	32.30	659.75	432.37	1,065.01	65.36
Cash Flow from Investing Activities	-16.39	-71.34	-334.73	-79.97	30.80
Cash from Financing Activities	-15.82	-205.34	-38.32	-881.32	-65.59
Net Cash Inflow / Outflow	0.09	383.07	59.32	103.72	30.57

	Parnax Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	14.71	26.21	26.22	13.59	21.29
ROE (%)	10.86	19.16	19.73	18.75	20.76
ROA (%)	4.29	14.95	18.69	9.26	9.67
EBIT Margin (%)	6.27	34.40	31.41	26.58	8.74
Net Margin (%)	3.50	26.88	28.10	20.60	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Parnax Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	31.93	10.69	15.01	9.59	31.10
EBIT Growth (%)	-12.71	24.14	18.45	16.84	-12.99
Net Profit Growth (%)	-17.36	-9.09	19.61	62.68	-7.49
EPS Growth (%)	-7.00	14.40	17.73	67.41	-18.33
Book Value Growth (%)	16.10	17.30	23.77	10.19	7.70

	Parnax Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	15.31	27.87	28.74	27.66	102.37
Price / Book Value	1.61	4.88	5.08	4.51	19.65
Dividend Yield (%)	0.00	1.60	0.16	0.55	0.51
EV/EBITDA	8.78	19.53	22.88	17.94	75.34
Market Cap (₹ Cr)	122.89	18,318.10	15,219.80	19,292.77	21,515.93

	Parnax Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.23	0.00	0.00	0.24	0.00
Short term debt to equity ratio	0.43	0.00	0.00	0.14	--
Current Ratio	0.97	6.06	6.70	0.74	1.77
Quick Ratio	0.59	5.31	5.59	0.53	0.73
Interest Coverage	2.97	130.11	959.59	4.45	40.90

	Parnax Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	15.01	7.07	36.10	21.07	8.79
Asset Turnover	1.21	0.52	0.63	0.45	1.39
Receivable days	61.56	29.10	110.70	54.07	35.81
Inventory Days	54.14	69.53	65.86	32.16	82.25
Payable days	85.60	76.77	105.88	140.91	124.39
Cash Conversion Cycle	30.10	21.86	70.68	-54.68	-6.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.